Trial characteristics
| Trial . | Design . | Phase . | Disease . | Type . | Age, median (range), y . | Total enrolled . | Ineligible, analyzed, n (%) . | Ineligible, not analyzed, n (%) . | Did not receive protocol therapy*; not analyzed, n (%) . | Analyzed, n (%) . |
|---|---|---|---|---|---|---|---|---|---|---|
| S0106 | R | 3 | AML | DN | 47 (18, 60) | 637 | 16 (3) | 39 (6) | 3 (1) | 595 (93) |
| S0301 | S | 2 | AML | DN | 66 (58, 82) | 69 | 2 (3) | 2 (4) | 3 (4) | 64 (93) |
| S0325 | R | 2 | CML | DN | 50 (19, 91) | 403 | 46 (11) | 9 (3) | 5 (1) | 389 (97) |
| S0333 | S | 2 | ALL | DN | 43 (18, 64) | 79 | 10 (14) | 2 (3) | 3 (4) | 74 (94) |
| S0432 | R | 2 | AML | DN | 78 (70, 96) | 348 | 33 (9) | 7 (2) | 10 (3) | 331 (95) |
| S0521 | R | 3 | APL | DN | 49 (20, 82) | 105 | 2 (2) | 0 (0) | 0 (0) | 105 (100) |
| S0530 | S | 2 | ALL | R/R | 42 (20, 68) | 37 | 9 (24) | 0 (0) | 1 (3) | 36 (97) |
| S0605 | S | 2 | AML | DN | 73 (60, 94) | 41 | 0 (0) | 3 (7) | 1 (3) | 37 (90) |
| S0703 | S | 2 | AML | DN | 73 (60, 88) | 142 | 8 (6) | 3 (2) | 6 (4) | 133 (94) |
| S0805 | S | 2 | ALL | DN | 44 (20, 60) | 97 | 10 (10) | 2 (2) | 1 (1) | 94 (97) |
| S0910 | S | 2 | ALL | R/R | 42 (21, 68) | 35 | 1 (3) | 3 (9) | 2 (6) | 30 (86) |
| S0919 | S | 2 | AML | R/R | 57 (23, 78) | 86 | 0 (0) | 3 (3) | 1 (1) | 82 (95) |
| S1117 | R | 2/3 | MDS | DN | 70 (28, 93) | 282 | 32 (11) | 5 (2) | 0 (0) | 277 (98) |
| Trial . | Design . | Phase . | Disease . | Type . | Age, median (range), y . | Total enrolled . | Ineligible, analyzed, n (%) . | Ineligible, not analyzed, n (%) . | Did not receive protocol therapy*; not analyzed, n (%) . | Analyzed, n (%) . |
|---|---|---|---|---|---|---|---|---|---|---|
| S0106 | R | 3 | AML | DN | 47 (18, 60) | 637 | 16 (3) | 39 (6) | 3 (1) | 595 (93) |
| S0301 | S | 2 | AML | DN | 66 (58, 82) | 69 | 2 (3) | 2 (4) | 3 (4) | 64 (93) |
| S0325 | R | 2 | CML | DN | 50 (19, 91) | 403 | 46 (11) | 9 (3) | 5 (1) | 389 (97) |
| S0333 | S | 2 | ALL | DN | 43 (18, 64) | 79 | 10 (14) | 2 (3) | 3 (4) | 74 (94) |
| S0432 | R | 2 | AML | DN | 78 (70, 96) | 348 | 33 (9) | 7 (2) | 10 (3) | 331 (95) |
| S0521 | R | 3 | APL | DN | 49 (20, 82) | 105 | 2 (2) | 0 (0) | 0 (0) | 105 (100) |
| S0530 | S | 2 | ALL | R/R | 42 (20, 68) | 37 | 9 (24) | 0 (0) | 1 (3) | 36 (97) |
| S0605 | S | 2 | AML | DN | 73 (60, 94) | 41 | 0 (0) | 3 (7) | 1 (3) | 37 (90) |
| S0703 | S | 2 | AML | DN | 73 (60, 88) | 142 | 8 (6) | 3 (2) | 6 (4) | 133 (94) |
| S0805 | S | 2 | ALL | DN | 44 (20, 60) | 97 | 10 (10) | 2 (2) | 1 (1) | 94 (97) |
| S0910 | S | 2 | ALL | R/R | 42 (21, 68) | 35 | 1 (3) | 3 (9) | 2 (6) | 30 (86) |
| S0919 | S | 2 | AML | R/R | 57 (23, 78) | 86 | 0 (0) | 3 (3) | 1 (1) | 82 (95) |
| S1117 | R | 2/3 | MDS | DN | 70 (28, 93) | 282 | 32 (11) | 5 (2) | 0 (0) | 277 (98) |
DN, de novo; R, randomized; R/R, relapsed/refractory; S, single arm.
Or withdrew consent directly after randomization.